Press Releases  
November 18, 2009  Epiphany Announces Positive Results from its Phase 2b trial in shingles
March 24, 2009  Epiphany Biosciences Initiates Program to Assess Valomaciclovir (EPB-348) as Adjunctive Therapy in Multiple Sclerosis (MS)
January 21, 2009  Students Still Getting Mono After All These Years (The New York Times, Health Guide)
September 9, 2008 Epiphany Biosciences to continue Phase 2 shingles study after interim analysis; plans follow-on clinical trial studying post-herpetic neuralgia (PHN)
February 12, 2008

Students test new mono treatment drug (The Minnesota Daily)
December 6, 2007  Epiphany Biosciences Reports Initiation of Phase 2 Study of Valomaciclovir for the Treatment of Acute Infectious Mononucleosis
November 7, 2007  Epiphany Biosciences Reports Initiation and Enrollment in Valomaciclovir Study for Shingles
March 15, 2007  Epiphany Biosciences Raises $36 Million Round in Private Financing
February 22, 2007  Michael Houghton, co-discoverer of Hepatitis C and Lasker Award Winner, to become Epiphany Biosciences’ Chief Scientific Officer
February 15, 2007  2006 Nobel Laureate Roger Kornberg to Join Epiphany Biosciences’ Scientific Advisory Board
September 8, 2006 Epiphany Biosciences licenses antiviral compound EPB-348 (MIV-606) from Medivir AB


Contact  |  Site Map

Copyright © 2009-2011 Epiphany Biosciences, Inc.